All stock lists
ORIX Corporation (New York Stock Exchange:IX)
JP · Delayed Price · Currency is USD
Financial Services · Financial - Credit Services
34.85-0.99 (-2.76%)
Market cap
$38.7B
Insider Score
Health Score
Listed since
Sep 16, 1998
Website
Insider Score
––Not scored
IX Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Sound
From IX’s reported statements · Q2 2026 (trailing 12 months)
Profitability19 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $3451.66B
- Net income
- $621.87B
- Net margin
- 18.0%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $6308.80B
- Cash
- $968.92B
- Net debt / EBITDA
- 4.17x
Liquidity16 / 20
Comfortably covers what is due within a year.
- Current assets
- $7793.26B
- Current liabilities
- $4645.53B
- Current ratio
- 1.68
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $1459.12B
- Free cash flow
- $1379.52B
- FCF margin
- 40.0%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 1098.9M
- Share growth (1y)
- -3.1%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 876.63 B | 938.86 B | 840.32 B | 795.86 B | 768.64 B | 720.34 B |
| Revenue Growth (YoY) | 14.05 % | 30.34 % | 11.92 % | 14.43 % | 8.54 % | -7.23 % |
| Cost of Revenue | 486.43 B | 612.25 B | 581.86 B | 552.78 B | 429.36 B | 424.15 B |
| Gross Profit | 390.20 B | 326.61 B | 258.46 B | 243.07 B | 339.29 B | 296.18 B |
| SG&A Expense | 197.82 B | 0.00 | 0.00 | 0.00 | 164.05 B | 175.86 B |
| R&D Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 256.28 B | -88.41 B | 87.36 B | 79.07 B | 209.53 B | 255.08 B |
| Operating Income | 133.92 B | 415.02 B | 171.10 B | 164.00 B | 129.75 B | 41.10 B |
| Pretax Income | 406.15 B | 125.98 B | 176.24 B | 236.00 B | 155.48 B | 97.09 B |
| Tax Provision | 125.58 B | 61.92 B | 55.68 B | 70.41 B | 46.21 B | 17.15 B |
| Net Income | 280.83 B | 58.65 B | 118.58 B | 163.81 B | 107.29 B | 79.85 B |
| EPS (Basic) | 251.55 | 54.33 | 106.81 | 145.81 | 94.63 | 70.28 |
| EPS (Diluted) | 251.55 | 54.33 | 106.48 | 145.47 | 94.44 | 70.14 |
| Shares Outstanding | 1.10 B | 1.08 B | 1.11 B | 1.13 B | 1.13 B | 1.14 B |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.